NCI's M-PACT Study Exploring PGx Strategy in Cancer Patients with Seldom Studied Driver Mutations | GenomeWeb

The success of a handful of pharmacogenetically-targeted cancer drugs, such as the BRAF inhibitor Zelboraf in melanoma or the ALK inhibitor Xalkori in non-small cell lung cancer, may have given rise to the assumption that any treatment that targets a particular pathway or mutation driving a tumor will benefit that patient.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."